[Treatment of patients with COVID-19 on Hemodialysis: Efficacy of Remdesivir]

Aya Nakaya; Morihiro Kondo; Eiji Ogura; Yuki Katayama; Eiko Yoshino; Kazuya Hozumi; Saori Tago; Yuko Teranishi; Yuki Minamibashi; Makiko Harada; Yuri Kawano; Yuka Arai; Mika Kobayashi; Airi Kouyama; Keno Yoshida; Shozo Shimizu; Kazuma Ogura; Katsuaki Iwashita; BOH Covid-19 Team

doi:10.1016/j.nefro.2022.07.004

[Treatment of patients with COVID-19 on Hemodialysis: Efficacy of Remdesivir]

Nefrologia. 2022 Aug 3. doi: 10.1016/j.nefro.2022.07.004. Online ahead of print.

[Article in Spanish]

Authors

Aya Nakaya¹, Morihiro Kondo¹, Eiji Ogura¹, Yuki Katayama¹, Eiko Yoshino¹, Kazuya Hozumi¹, Saori Tago¹, Yuko Teranishi¹, Yuki Minamibashi¹, Makiko Harada¹, Yuri Kawano¹, Yuka Arai¹, Mika Kobayashi¹, Airi Kouyama¹, Keno Yoshida¹, Shozo Shimizu¹, Kazuma Ogura¹, Katsuaki Iwashita¹; BOH Covid-19 Team

Affiliation

¹ Internal Medicine, Biwako Ohashi Hospital, 5-1-29 Mano, Otsu city, Shiga, 520-0232, Japan.

Abstract

Background: There is no standard therapy for hemodialysis (HD) patients with COVID-19. Data on remdesivir in HD patients with COVID-19 are scarce.

Methods: We retrospectively analyzed 25 HD patients with COVID-19 treated with remdesivir.

Results: The median age of the patients was 78 years (range, 45-92 years) and was predominantly male (84%). A total of 44% of the patients had mild disease, 36% had moderate-1, and 20% had moderate-2. The most common symptoms were fever (76%) and coughing (44%). The most common comorbidity was renal failure (100%), followed by hypertension (60%) and cardiac disease (44%). The most frequent biomarker was elevated creatinine (100%), followed by C-reactive protein (80%), lymphopenia (76%), and D-dimer (68%). C-reactive protein levels decreased significantly before and after remdesivir administration (p < 0.001). Two patients showed deterioration, but none died. All patients recovered from COVID-19 and no adverse effects of treatment with remdesivir were observed.

Conclusion: Our study suggests the safe use of remdesivir in HD patients with COVID-19.

Keywords: C-reactive protein; COVID-19; Hemodialysis; Remdesivir; Treatment.

Publication types

English Abstract